author-photo

Delphine Carmier

9

Papers

297

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.

2020 Journal of Clinical Medicine
Show All
- Source
- Cite
- Save
Citations (5)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (198)
Étude de phase II randomisée non comparative de l’anti-PD-L1 atézolizumab versus chimiothérapie comme traitement de deuxième ligne chez les patients atteints d’un cancer du poumon à petites cellules (CBPC) : résultats de l’essai IFCT-1603

2019 Revue Des Maladies Respiratoires
Show All
- Source
- Cite
- Save
Citations (0)
1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Metastatic Renal Cell Carcinoma Treated Sequentially with Multiple VEGF Receptor-targeted Inhibitors – A Case Report

2012 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (0)
What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)